NEW YORK – Natera said on Thursday that it is collaborating with Mass General Cancer Center of Massachusetts General Hospital on an early-stage breast cancer clinical trial of a molecularly targeted therapy.
The investigator-initiated, multi-center, Phase II randomized trial, called LEADER, will evaluate Ribociclib (Novartis' Kisqali), a CDK4/6 inhibitor, for the treatment of ER-positive breast cancer.